Attached files
file | filename |
---|---|
8-K - 8-K - Cardiff Oncology, Inc. | a15-15331_18k.htm |
Exhibit 99.1
Trovagene Inc. to Present at Cantor Fitzgeralds Inaugural Healthcare Conference
SAN DIEGO, CA July 7, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at Cantor Fitzgeralds Inaugural Healthcare Conference.
Trovagene is scheduled to present at Cantor Fitzgeralds Inaugural Healthcare Conference at Le Parker Meridien Hotel in New York, NY on July 8, 2015 at 1:30 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://wsw.com/webcast/cantor2/trov and can also be accessed through our investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Companys technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagenes precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
# # #
Contact
Investor Relations |
|
Media Relations |
David Moskowitz and Amy Caterina |
|
Ian Stone |
Trovagene, Inc. |
|
Canale Communications, Inc. |
858-952-7593 |
|
619-849-5388 |
ir@trovagene.com |
|
ian@canalecomm.com |
Trovagene Inc. | 11055 Flintkote Avenue | San Diego | CA 92121 | Tel.: USA [+1] 888-391-7992